Primary antibody notesThis antibody blocks in vitro binding of lymphocytes to peripheral lymph node HEV and inhibits in vivo lymphocyte extravasation into peripheral lymph nodes and the late stages of leukocyte rolling.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use 2µg for 106 cells. ab18446-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
Use at an assay dependent concentration.
Use at an assay dependent concentration. In vivo and in vitro blocking of adhesion: Use at an assay dependent dilution.Cytotoxicity studies: Use at an assay dependent dilution.
FunctionCell surface adhesion protein. Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. Promotes initial tethering and rolling of leukocytes in endothelia.
Tissue specificityExpressed in B cell lines and T lymphocytes.
Sequence similaritiesBelongs to the selectin/LECAM family. Contains 1 C-type lectin domain. Contains 1 EGF-like domain. Contains 2 Sushi (CCP/SCR) domains.
References for Anti-CD62L antibody [MEL-14] (FITC) (ab24876)
This product has been referenced in:
Morrison VL et al. TLR-mediated loss of CD62L focuses B cell traffic to the spleen during Salmonella typhimurium infection. J Immunol185:2737-46 (2010).
Read more (PubMed: 20660707) »
Reichert RA et al. Dual immunofluorescence studies of cortisone-induced thymic involution: evidence for a major cortical component to cortisone-resistant thymocytes. J Immunol136:3529-34 (1986).
Read more (PubMed: 3084633) »